Under the partnership, Glympse Bio’s synthetic biomarkers will be used to determine clinical trial participants’ stage of disease at first screening.
Responses to study treatment will be identified in Gilead’s NASH clinical development programme.
These biomarkers are bioengineered to identify disease progression and stage, as well as early detection of treatment response.
Gilead Sciences Liver Diseases senior vice-president Mani Subramanian said: “We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development programme.
“By utilising this innovative technology, we hope to better characterise this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s technology Glympse Inside is capable of identifying the stage and monitoring the progression of life-threatening diseases such as cancer, fibrosis, and inflammation, as well as infections in real-time by combining synthetic biomarkers with machine learning approaches.
It is a comprehensive database of real-time biological activity in the human body, which generates insights to validate drug-target engagement and drive earlier and stronger outcomes for patients.
Glympse Bio president and CEO Caroline Loew said: “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
In April this year, Gilead Sciences entered a clinical collaboration with Novo Nordisk to evaluate a combination treatment for NASH.